Plus Therapeutics Secures AMA CPT Code To Boost Adoption and Reimbursement Of CNSide CSF Tumour Cell Test

Plus Therapeutics, Inc. has announced that the American Medical Association has approved a new Proprietary Laboratory Analyses (PLA) Current Procedural Terminology (CPT) code for its CNSide® Cerebrospinal Fluid Tumor Cell Enumeration (TCE) test. The new billing code, 0640U, will take effect on July 1, 2026, and is expected to support reimbursement and broader clinical adoption of the diagnostic platform.

The CNSide CSF TCE test is designed to detect and quantify tumor cells in cerebrospinal fluid, helping clinicians evaluate patients with suspected leptomeningeal metastases. The introduction of a dedicated CPT code provides a standardized framework for claims submission, making it easier for healthcare providers and payers to process and evaluate reimbursement requests.

“Securing a dedicated PLA code for CNSide is an important milestone supporting the commercial launch of our CNSide Diagnostics business,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “This coding milestone simplifies the reimbursement pathway for the CNSide CSF Tumor Cell Enumeration test and supports broader clinical adoption by oncologists and neurologists managing patients with leptomeningeal metastases. As awareness and payer coverage expand, we believe CNSide has the potential to become an important tool in the management of metastatic CNS cancers while contributing meaningfully to our revenue growth. Our diagnostics business continues to scale alongside our therapeutic pipeline, and we remain focused on building CNSide into a sustainable commercial franchise.”

This development is also expected to streamline clinical workflows by simplifying the ordering and billing process for physicians and cancer centers. Additionally, the PLA code enables tracking test use through national claims data, which can support the generation of real-world evidence on clinical outcomes and economic impact.

Overall, the new coding milestone strengthens the reimbursement infrastructure for Plus Therapeutics as it continues the U.S. commercial rollout of its CNSide diagnostic platform, potentially accelerating adoption and improving access to advanced CNS cancer diagnostics.